Oppenheimer Reiterates Outperform on Regulus Therapeutics, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Andreas Argyrides has reiterated an Outperform rating on Regulus Therapeutics (NASDAQ:RGLS) and maintained a price target of $7.
August 14, 2024 | 5:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Andreas Argyrides has reiterated an Outperform rating on Regulus Therapeutics (NASDAQ:RGLS) and maintained a price target of $7.
The reiteration of an Outperform rating and the maintenance of a $7 price target by a reputable analyst can boost investor confidence in Regulus Therapeutics, potentially leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100